AIMC Topic: Uveal Neoplasms

Clear Filters Showing 11 to 17 of 17 articles

Robotic Extended Ultrasound-Guided Distal Pancreatectomy for Pancreatic Metastases from Uveal Melanoma.

Annals of surgical oncology
BACKGROUND: Isolated pancreatic metastasis from melanoma is extremely uncommon and accounts for approximately only 2% of visceral disseminations of melanoma. Interestingly, pancreatic localizations disproportionately derive from primary ocular melano...

Piloting a Deep Learning Model for Predicting Nuclear BAP1 Immunohistochemical Expression of Uveal Melanoma from Hematoxylin-and-Eosin Sections.

Translational vision science & technology
BACKGROUND: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Monosomy 3 and mutation are strong prognostic factors predicting metastatic risk in UM. Nuclear BAP1 (nBAP1) expression is a close immunohistochemical surro...

Stereotactic Radiation Therapy or Protons for Uveal Melanoma Patients? An Artificial Intelligence (AI)-Based Clinical Treatment Decision-Making Tool Predicting Doses To Radiation Therapy Constraints.

International journal of radiation oncology, biology, physics
PURPOSE: For ocular melanoma, selecting between stereotactic radiation therapy (SRT) and protons requires a lengthy plan comparison process. The purpose of this brief report is to describe an artificial intelligence (AI) decision-making tool to predi...

Machine learning-based integrative analysis of methylome and transcriptome identifies novel prognostic DNA methylation signature in uveal melanoma.

Briefings in bioinformatics
Uveal melanoma (UVM) is the most common primary intraocular human malignancy with a high mortality rate. Aberrant DNA methylation has rapidly emerged as a diagnostic and prognostic signature in many cancers. However, such DNA methylation signature av...

Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma.

American journal of clinical oncology
OBJECTIVE: Prognosis of patients with metastatic melanoma has dramatically improved over recent years because of the advent of antibodies targeting programmed cell death protein-1 (PD1). However, the response rate is ~40% and baseline biomarkers for ...